BJCT Financials Monday, July 14, 2014 11:48:12 PM
Post# of 9
Posted On: 07/14/2014 11:48:15 PM
BJCT Financials Monday, July 14, 2014 11:48:12 PM
Bioject Medical Technologies Inc.
Period Ending Dec 31, 2010
Total Revenue 5,577
Cost of Revenue 3,864
Gross Profit 1,713
Operating Expenses
Research and Development 1,355
Sales, General and Admin. 2,045
Non-Recurring Items -
Other -
Operating Income (1,688)
Income From Continuing Operations
Add'l Income/Expense Items 252
Earnings Before Interest and Tax (1,436)
Interest Expense 39
Earnings Before Tax (1,475)
Income Tax -
Minority Interest -
Equity Earnings Unconsolidated Subsidiary -
Net Income Cont. Operations (1,475)
Non Recurring Events
Discontinued Operations -
Extraordinary Items -
Effect of Accounting Changes -
Other Items -
Net Income (1,475)
Preferred Stock and Other Adjustments (98)
Net Income Applicable to Common Shareholders (1,572)
Bioject Medical Technologies Inc.
Period Ending Dec 31, 2010
Total Revenue 5,577
Cost of Revenue 3,864
Gross Profit 1,713
Operating Expenses
Research and Development 1,355
Sales, General and Admin. 2,045
Non-Recurring Items -
Other -
Operating Income (1,688)
Income From Continuing Operations
Add'l Income/Expense Items 252
Earnings Before Interest and Tax (1,436)
Interest Expense 39
Earnings Before Tax (1,475)
Income Tax -
Minority Interest -
Equity Earnings Unconsolidated Subsidiary -
Net Income Cont. Operations (1,475)
Non Recurring Events
Discontinued Operations -
Extraordinary Items -
Effect of Accounting Changes -
Other Items -
Net Income (1,475)
Preferred Stock and Other Adjustments (98)
Net Income Applicable to Common Shareholders (1,572)
(0)
(0)Bioject Medical Technologies Inc. (BJCT) Stock Research Links
Scroll down for more posts ▼